Observational studyClinical journal of the American Society of Nephrology : CJASN2018
Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.
Observational study in Clinical journal of the American Society of Nephrology : CJASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Review
- Ultrafiltration rate and mortality in patients undergoing extended-hours haemodialysis.Clinical kidney journal · 2025Article
- Longitudinal impact of extended-hours hemodialysis with a liberalized diet on nutritional status and survival outcomes: findings from the LIBERTY cohort.Clinical and experimental nephrology · 2025Article
- Can Intermittent Hemodialysis Normalize Plasma Solute Levels?Kidney360 · 2025Article
- Plasma Metabolite Profiles Between In-Center Daytime Extended-Hours and Conventional Hemodialysis.Kidney360 · 2025Article
- The microbial metabolite trimethylamine N-oxide and the kidney diseases.Frontiers in cellular and infection microbiology · 2025Review
- The Choice of Anti-Inflammatory Influences the Elimination of Protein-Bound Uremic Toxins.Toxins · 2024Article
- A Metabolomics Approach to Identify Metabolites Associated With Mortality in Patients Receiving Maintenance Hemodialysis.Kidney international reports · 2024Article
- Metabolic Pathways Affected in Patients Undergoing Hemodialysis and Their Relationship with Inflammation.International journal of molecular sciences · 2024Article
- Assessment of Within- and Inter-Patient Variability of Uremic Toxin Concentrations in Children with CKD.Toxins · 2024Article
- Indoxyl Sulfate Contributes to Impaired Height Velocity in (Pre)School Children.Kidney international reports · 2024Article
- Plasma metabolites and physical function in patients undergoing hemodialysis.Scientific reports · 2024Article
- Avenues for post-translational protein modification prevention and therapy.Molecular aspects of medicine · 2022Review
- Article
- Beta-2 Microglobulin Amyloidosis: Past, Present, and Future.Kidney360 · 2020Review
- Potential Biomarkers of the Turnover, Mineralization, and Volume Classification: Results Using NMR Metabolomics in Hemodialysis Patients.JBMR plus · 2020Article
- Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.Arteriosclerosis, thrombosis, and vascular biology · 2020Article
- Kidney Clearance of Secretory Solutes Is Associated with Progression of CKD: The CRIC Study.Journal of the American Society of Nephrology : JASN · 2020Article
- Optimized vs. Standard Automated Peritoneal Dialysis Regimens (OptiStAR): study protocol for a randomized controlled crossover trial.Pilot and feasibility studies · 2020Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
objectivesIn-center, extended duration nocturnal hemodialysis has been associated with variable clinical benefits, but the effect of extended duration hemodialysis on many established uremic solutes and other components of the metabolome is unknown. We determined the magnitude of change in metabolite profiles for patients on extended duration nocturnal hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a 52-week prospective, observational study, we followed 33 patients receiving conventional thrice weekly hemodialysis who converted to nocturnal hemodialysis (7-8 hours per session, three times per week). A separate group of 20 patients who remained on conventional hemodialysis (3-4 hours per session, three times per week) served as a control group. For both groups, we applied liquid chromatography-mass spectrometry-based metabolite profiling on stored plasma samples collected from all participants at baseline and after 1 year. We examined longitudinal changes in 164 metabolites among those who remained on conventional hemodialysis and those who converted to nocturnal hemodialysis using Wilcoxon rank sum tests adjusted for multiple comparisons (false discovery rate <0.05).
resultsOn average, the nocturnal group had 9.6 hours more dialysis per week than the conventional group. Among 164 metabolites, none changed significantly from baseline to study end in the conventional group. Twenty-nine metabolites changed in the nocturnal group, 21 of which increased from baseline to study end (including all branched-chain amino acids). Eight metabolites decreased after conversion to nocturnal dialysis, including l-carnitine and acetylcarnitine. By contrast, several established uremic retention solutes, including
conclusionsAcross a wide array of metabolites examined, extended duration hemodialysis was associated with modest changes in the plasma metabolome, with most differences relating to metabolite increases, despite increased dialysis time. Few metabolites showed reduction with more dialysis, and no change in several established uremic toxins was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.